RxDoctor Payments Data

Albert Musaffi, MD

Cardiovascular Disease · Wellington, FLNPI 1619924446

Payments from drug & device makers

$3,247in general payments, 2019–2025

Across 177 payments — averaging $18.34 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Amgen$628
  • Novartis$595
  • E.r. Squibb & Sons, L.L.C.$407
  • Johnson & Johnson$265
  • Abbott$239
  • Boehringer Ingelheim$210
  • plus $903 from 19 others

What the payments were for

  • Food & beverage$3,22099%
  • Education$261%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,247 in reported general payments places this provider in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

See all cardiovascular disease providers in Florida

Medicare billing

Part B allowed, 2024
$279,750
Medicare patients
669
Services billed
3,047

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban428$429,094
XareltoRivaroxaban99$120,623
Repatha SureclickEvolocumab137$96,985
EntrestoSacubitril/Valsartan55$53,064
MultaqDronedarone Hcl31$34,135
Repatha SyringeEvolocumab51$28,070
JardianceEmpagliflozin11$9,648
Metoprolol Succinate569$6,838
Dabigatran EtexilateDabigatran Etexilate Mesylate13$4,889
Olmesartan Medoxomil298$4,776
Nebivolol Hcl81$3,944
Midodrine Hcl50$2,784
Diltiazem 24hr Er (Cd)Diltiazem Hcl91$2,782
Rosuvastatin Calcium239$2,255
Flecainide Acetate50$2,084

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$121$429,094428 claims
Johnson & JohnsonXarelto$265$120,62399 claims
NovartisEntresto$595$53,06455 claims
Sanofi-aventis U.S. LLCMultaq$42$34,13531 claims
Boehringer IngelheimJardiance$210$9,64811 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 45th percentile of 1,740 cardiovascular disease providers in Florida.

Other cardiovascular disease in Wellington

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →